

▶ Monday, 9 September 2019

MD-01 2-Day MD Symposium

08:30–09:30 Clio

Selected Abstracts

Chairs: *Cristina Teixeira, Spain**Bastiaan Tops, The Netherlands*

001 08:30–08:42

Plasma cfDNA testing of patients with EGFR mutant non-small cell lung cancer: droplet-digital PCR versus next-generation sequencing compared to tissue-based results

Hendrikus Jan Dubbink, The Netherlands

P. N. Atmodimedjo, E. de Jonge, M. Paats, C. van der Leest, E. Oomen - de Hoop, J. van der Thüsen, W. Dinjens, R. H. van Schaik, J. Aerts, C. M. J. Steendam

002 08:42–08:54

Circulating Cell-free DNA in archived low quality volume serum samples: Rate of concordance with mutation in tumour

Behnoush Abedi-Ardekani, France

D. Nasrollahzadeh, T. Delhomme, P. H. Avogbe, M. Foll, J. McKay, P. Brennan, R. Malekzadeh

003 08:54–09:06

Global delivery of external quality assessment for lung cancer liquid biopsy testing

Zandra Deans, United Kingdom

J. Fairley, M. Cheetham, M. Denis, E. Dequeker, C. Keppens, F. Fenizia, N. Normanno, S. Patton, E. Rouleau, E. Schuurin, K. van Casteren

004 09:06–09:18

Reflex tumour BRCA1/2 testing in ovarian carcinomas to stratify PARP inhibitor treatment and germline diagnostics

Marjolijn Ligtenberg, The Netherlands

J. R. Vos, I. E. Fakkert, J. A. de Hullu, A. M. van Altena, A. S. Sie, H. Ouchene, R. W. Willems, I. Nagtegaal, M. C. Jongmans, A. R. Mensenkamp, G. H. Woldringh, J. Bulten, E. M. Leter, C. M. Kets, M. Simons, N. Hoogerbrugge

005 09:18–09:30

Exploitation of cfDNA extracted from bile as liquid biopsy source in pancreaticobiliary cancers

Caroline Driescher, Germany

K. Ebner, W. Goering, L. Haeberle, V. Keitel, D. Haussinger, I. Esposito

MD-02 2-Day MD Symposium

10:30–12:00 Clio

Preanalytics

Chairs: *Frederick Klauschen, Germany**Erik Jan Dubbink, The Netherlands*

001 10:30–11:00

Where a reliable biomarker is born: a new pathology preanalytics in XXIst century

Antonio Martinez, Spain

002 11:00–11:30

Parallel sequencing after cell separation from FFPE material

*Janna Siemanowski, Germany**(supported by Miltenyi Biotec)*

003 11:30–12:00

Suitability of cytological specimen for NGS testing

Giancarlo Troncone, Italy

MD-03 2-Day MD Symposium

14:45–16:45 Clio

Quality assurance and guidelines in molecular pathology

Chairs: *Nicola Normanno, Italy**Etienne Rouleau, France*

001 14:45–15:09

ESP EQAs: impact on quality improvement

Aleš Ryška, Czech Republic

002 15:09–15:33

IQN PATH: ring trial on TMB testing

Francesca Fenizia, Italy

003 15:33–15:39

IQN PATH: ring trial on liquid biopsy – introduction of trial concept

Jennifer Fairley, United Kingdom

004 15:39–15:57

IQN PATH: ring trial on liquid biopsy – results from the ESP-EQA

Kaat van Casteren, Belgium

005 15:57–16:21

UK NEQAS: NGS, variant nomenclature and reporting

Jennifer Fairley, United Kingdom
006 16:21–16:45

French quality assurance programme Gen&tiss

Karen Leroy, France
MD-04 2-Day MD Symposium
17:15–19:15 **Clio**
NGS – beyond mutation testing
Chairs: Marjolijn Ligtenberg, The Netherlands
Sabine Merkelbach-Bruse, Germany
001 17:15–17:45

 AMP guidelines for variant reporting
Marilyn Li, USA
Planned jointly with AMP
002 17:45–18:15

 CNV detection from NGS data
Astrid Eijkelenboom, The Netherlands
003 18:15–18:45

 Fusion gene detection using RNAseq
Bastiaan Tops, The Netherlands
004 18:45–19:15

 Moving beyond DNA sequence: genome-wide profiling of plasma DNA
Samantha Perakis, Austria
► Tuesday, 10 September 2019
MD-05 2-Day MD Symposium
08:30–09:30 **Clio**
Selected Abstracts
Chairs: Sabine Merkelbach-Bruse, Germany
Etienne Rouleau, France
001 08:30–08:42

Differentially expressed immune related genes in metastatic vs. non-metastatic LUMA, LUMB1 and TNBC primary breast carcinoma cases

Anna Maria Tokes, Hungary
O. Ruzs, C. Pollner-Szundi, L. Madaras, A. Kovács, B. Molnár, I. Vári-Kakas, J. Kulka
002 08:42–08:54

Tumour mutational burden analysis: implementation in routine diagnostics

Leonie Kroeze, The Netherlands
E. Kamping, D. von Rhein, E. Jansen, R. de Voer, M. Barberis, J. Botling, E. Garrido-Martin, F. Haller, L. Lacroix, B. Maes, S. Merkelbach-Bruse, V. Pestinger, N. Pfarr, A. Stenzinger, K. Grünberg, M. Ligtenberg
003 08:54–09:06

Role of HR23b in response to HDAC inhibitors and their effect on immunotherapy targets

Svenja Wagener-Rydzek, Germany
C. Alidousty, C. Heydt, J. Fassunke, S. Merkelbach-Bruse, R. Buettner, M. A. Ihle
004 09:06–09:18

MET exon 14 skipping mutations in non small cell lung cancer: efficient routine diagnostics, histopathology and clinical response upon targeted treatment

Willemina Geurts-Giele, The Netherlands
M. Pruis, J. von der Thüsen, I. Meijssen, W. Dinjens, J. Aerts, M. Lolkema, M. Paats, H. J. Dubbink
005 09:18–09:30

The diagnostic landscape and yield of predictive somatic molecular analyses for stratification of cancer therapy in The Netherlands

Elisabeth Steeghs, The Netherlands
E. K. de Jong, R. W. Willems, Q. J. Voorham, P. A. Seegers, K. Grünberg, M. Ligtenberg

MD-06	2-Day MD Symposium
10:30–12:00	Clio
Mutational signatures and bioinformatics	
Chairs: Frederick Klauschen , Germany Bastiaan Tops , The Netherlands	

001 10:30–11:00

Signal: the homepage of mutational signatures

Jan Czarnecki, United Kingdom

002 11:00–11:30

A new user-friendly web application to implement mutational signatures analysis

Marcos Diaz-Gay, Spain

003 11:30–12:00

Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy

Nadine Gaisa, Germany

MD-07	2-Day MD Symposium
14:45–16:45	Clio
Immunooncology	
Chairs: Marjolijn Ligtenberg , The Netherlands Cristina Teixeira , Spain	

001 14:45–15:15

Multiplexed immunohistochemistry: from translational research to daily practice, is it realistic?

Paul Hofman, France

002 15:15–15:40

TMB and mutation testing by TSO500 and FoundationOneCDx in NSCLC

Johan Botling, Sweden
(supported by Illumina)

003 15:40–16:05

Comparison of TMB testing by Oncomine TML and FMI

Carina Heydt, Germany
(supported by ThermoFisher)

004 16:05–16:15

Discussion of talk 002 and 003

005 16:15–16:45

Molecular residual disease in early-stage NSCLC: lung TRACERx experience

Chris Abosh, United Kingdom
(supported by BMS)

MD-08	2-Day MD Symposium
17:15–19:15	Clio
New technologies	
Chairs: Erik Jan Dubbink , The Netherlands Carina Heydt , Germany	

001 17:15–17:45

Gene fusions in melanoma and/or skin

Arnaud de la Fouchardière, France

002 17:45–18:15

NanoString transcript analysis for the detection of gene fusion events

Leon van Kempen, The Netherlands

003 18:15–18:45

Proteogenomic tumour profiling

Frederick Klauschen, Germany

004 18:45–19:15

Methylation analysis – a new approach to sarcoma classification

Andreas von Deimling, Germany

► **Monday, 9 September 2019 /**

► **Tuesday, 10 September 2019**

PS-MD-01 **2-Day MD Symposium**

09:30 – 10:30 **Agora 3**

Poster Session

Chair: Sabine Merkelbach-Bruse, Germany

001

Expression of transient receptor potential Vanilloid-1 in gliomas vs medulloblastomas
Martha Assimakopoulou, Greece
A. Moutafidi, V. Zolota, G. Gatzounis

002

Validation of a novel approach for molecular breast cancer classification
Shawn Baldacchino, Malta
J. Debattista, C. Saliba, C. Scerri, G. Grech

003

Characterisation of genetic mutation spectra and identification of gene amplification and fusion variants in cell-free nucleic acid from cultured cancer cell media and liquid biopsy specimens using Oncomine™ pan-cancer cell-free assay
Ru Cao, USA

K. Lea, J. Schageman, K. Hanif, Y. Li, J. Gu, V. Bagai, P. Kshatriya, A. Luchetti, L. Quagliata, H. Wikman, S. Loges, K. Bramlett

004

Case report: NGS of cell-free DNA from blood and bile as a follow-up strategy in a patient with metastatic pancreatic adenocarcinoma

Katharina Ebner, Germany
C. Driescher, W. Goering, L. Haerberle, V. Keitel, D. Haussinger, I. Esposito

005

Effect of radio-wave and molecular resonance surgery on rat neck skin regeneration

Igor Kastyro, Russia
P. Pryanikov, A. Alsufev, V. Popadyuk, A. Kovalenko, A. Sedelnikova, N. Kamanina

006

Up-converting nanoparticles as a tool for histopathological tissue evaluation with multiplexing and machine learning potential

Krzysztof Krawczyk, Sweden
S. Andersson-Engels, A. Sjögren

007

Pathohistological characteristics of breast cancer in BRCA-positive and BRCA-negative women

Snjezana Ramic, Croatia
I. Kirac, T. Oresic, T. Zigman, V. Musani, P. Ozretic, O. Vugrek, I. Milas

008

Comparison of four microsatellite instability testing methods in endometrial cancer – reliability, handling, cost effectiveness
Janna Siemanowski, Germany
B. Schömig-Markiefka, W. Dietmaier, N. Arens, T. Buhl, R. Büttner, S. Merkelbach-Bruse

009

Association between KRAS, NRAS, BRAF mutation status and clinicopathological prognostic factors in colorectal carcinoma in Turkish population
Duygu Unal Kocabey, Turkey
E. Cakir, F.H. Dilek, B. Bolat Kucukzeybek, A. Calli

010

Results of the Belgian ring trial for liquid biopsy testing in non-small cell lung cancer show variety in the interpretation of the test result
Kaat van Casteren, Belgium
K. Dufraing, P. Pauwels, N. D'Haene, E. Dequeker

011

Establishment of a 3D histopathology platform for precision tumour diagnosis
Jialing Yang, Taiwan
Y. Lin, A. Chiang, I. Wang, S. Wu, M. D. Chang, J. Lee, J. Ko, S. Liang, J. Guo, X. Song, H. Huang, M. Chao, C. Lin